Dermatol. praxi. 2017;11(2):86-88 | DOI: 10.36290/der.2017.017

Resistant form of severe plaque psoriasis successfully managed with secukinumab

MUDr. Martin Tichý, Ph.D.
Klinika chorob kožních a pohlavních LF UP a FN Olomouc

Secukinumab, IL 17A inhibitor, belongs to the newer group of biological agents which are registered for therapy of severe plaque

psoriasis. The results of clinical trials and present clinical experience show very good efficacy and safety of secukinumab. Good

experience in the therapy of resistant and complicated forms of psoriasis is documented on concrete clinical case.

Keywords: secukinumab, resistant psoriasis, interleukin 17

Published: June 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tichý M. Resistant form of severe plaque psoriasis successfully managed with secukinumab. Dermatol. praxi. 2017;11(2):86-88. doi: 10.36290/der.2017.017.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Reszke R, Szepietowski JC. Secukinumab in the treatment of psoriasis: an update. Immunotherapy 2017 Feb 6; Epub ahead of print. Go to original source... Go to PubMed...
    2. Tichy M, Zapletalova J. Experience with systemic treatment of severe forms of psoriasis. Biomed pap. 2012; (1): 29-40. Go to original source... Go to PubMed...
    3. Farhangian ME, Feldman SROV. Immunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexate. Am J Clin Dermatol 2015; 16(4): 285-294. Go to original source... Go to PubMed...
    4. Blauvelt A. Safety of secukinumab in the treatment of psoriasis. Expert Opin Drug Saf 2016; 15(10): 1413-1420. Go to original source... Go to PubMed...
    5. Onishi RM, Gaffen SL. Interleukin - 17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 2010; 129(3): 311-321. Go to original source... Go to PubMed...
    6. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K et al. Secukinumab in plaque psoriasis - results of two phase 3 trials. N Engl J Med 2014; 371(4): 326-338. Go to original source... Go to PubMed...
    7. McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015; 386(9999): 1137-1146. Go to original source... Go to PubMed...
    8. Thaci D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol 2015; 73(3): 400-409. Go to original source... Go to PubMed...
    9. Mease P, McInnes IB. Secukinumab: A New Treatment Option for Psoriatic Arthritis. Rheumatol Ther 2016; 3(1): 5-29. Go to original source... Go to PubMed...

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.